Epicutaneous and / or intralymphatic immunotherapy for nasal allergy

Epicutaneous and / or intralymphatic immunotherapy for nasal allergy - Epicutaneous and / or intralymphatic immunotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015278

Enrollment

Registered

2014-10-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

Intralymphatic total12week, 2 JAU 0.02ml/w x 3 times epicutaneous total4week, 2000 JAU 0.2ml/w x 4 times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese cedar pollinosis

Exclusion criteria

Exclusion criteria: asthma under immunotherapy

Design outcomes

Primary

Measure	Time frame
nasal symptom score during the pollen season	—

Countries

Japan

Contacts

Public ContactTerada Tetsuya

Osaka Medical College Otorhinolaryngology

oto056@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026